Proviasette Logo
Your science demands it, we have the solution.

About Provia Laboratories

Provia Labs provides pharmaceutical, medical center, and private laboratories with high performance human tissue biospecimen storage containers and kit solutions.

To learn more, visit

Provia's Proviasette™ containers are specifically designed for the efficient storage and tracking of frozen human biospecimens, optimizing tissue management and maximizing the productivity of tissue banks.

The Team

Management Team

Board of Directors


The Provia Management Team

  • Connect on LinkedIn

Howard Greenman

Chief Executive Officer
Mr. Greenman was most recently Vice President and Interim CEO for HealthCare IT, Inc. (HCIT) – a biomedical software and services firm specializing in human tissue banking. While at HCIT, he formed partnerships with global pharmaceutical companies as well as major academic medical institutions to standardize the management of donated human specimens by using advanced logistics and clinical data management software and protocols. Prior to HCIT, Mr. Greenman led the strategic marketing function for Philips Medical System's Remote Patient Management Division, part of Philip's New Ventures organization. In this role, Mr. Greenman was responsible for commercialization and partnership strategy for a cardiovascular disease management platform technology. Prior to Philips, Mr. Greenman was Director of Business Development for Ardais Corporation, a biorepository management company that set the standard in tissue banking bioethics, logistics, and quality by building one of the largest repositories of research quality commercially available cancer tissue in the world. Mr. Greenman was the founder of medXtend Corporation, a venture backed healthcare services company providing medical devices and services for use by Radiologists and Primary Care Physicians. Additionally, Mr. Greenman worked in a variety of healthcare consulting roles within Accenture's Healthcare Practice, KPMG Peat Marwick's Healthcare Strategy Group, Oracle, and the Boston Consulting Group.
Mr. Greenman holds an M.B.A. from the Wharton School of Business in Healthcare Management.Back to Top ⇧

Dr. Peter Verlander

Chief Scientific Officer
Dr. Verlander was most recently the Associate Director for Strategic Development of the Laboratory for Molecular Medicine (LMM) within the Harvard Medical School - Partners Healthcare Center for Genetics and Genomics, where he helped transform the vision of personalized medicine into reality by translating research discoveries into breakthrough molecular diagnostic tests. Dr. Verlander led the team that developed the first clinical test for detection of EGFR mutations predicting therapeutic response in lung adenocarcinoma. Dr. Verlander is a molecular geneticist with nearly 15 years of experience in various aspects of human genetics in both academia and industry, including research at The Rockefeller University in New York on the molecular genetics of Fanconi anemia (FA), a DNA breakage disorder leading to bone marrow failure and increased risk of leukemia. In 2000, Dr. Verlander came to Boston to join Millennium Predictive Medicine’s Patient Management effort before joining the LMM in 2003.
Dr. Verlander received his PhD in Microbiology from Duke University.Back to Top ⇧

Bruce Meckling

Vice President, Global Marketing and Sales
Mr. Meckling brings to the Provia Labs team over two decades of Professional and Consumer Marketing, Sales Management, Business Development and General Management experience in the dental care and eye care industries, at leading high growth companies both large and small.

He served as VP International at Optiva Corporation, makers of the Sonicare electric toothbrush, now the oral care division of Royal Philips Electronics. At Bausch & Lomb Inc, he held the role of General Manager of Distributor Operations for Europe, the Middle East and Africa, after serving in progressive marketing and sales roles.

Mr. Meckling specializes in the international development of marketing and sales channels for professionally recommended healthcare products and services. He has special expertise in applying a blend of professional and consumer marketing to varied commercial models – strategic partnerships, direct sales subsidiaries and local agencies – based on optimal market structure. He lived and worked in Europe for nine years, and has traveled for business in over 40 countries worldwide. Back to Top ⇧

Gail Wiseman

Senior Manager, Biobanking
Gail Wiseman joins Provia Laboratories from HealthCare IT, Inc. (HCIT), a biomedical services firm specializing in human tissue banking. While at HCIT she worked closely with health care and life sciences professionals at academic medical research centers, pharmaceutical and biotech companies, and commercial biobanking laboratories deploying best in class procedures for human tissue collection, transport, and preservation.  Ms. Wiseman focused on defining the workflows and information requirements at diverse biospecimen collection sites.  She then managed the implementation of information technology and procedures to support patient consenting, tissue handling, and sample logistics through training and ongoing support.

Prior to HCIT, Ms. Wiseman was the Product Manager for Ardais Corporation, a biorepository management company that set the standard in tissue banking bioethics, logistics, and quality by building one of the largest repositories of research quality commercially available human tissue in the world.  While at Ardais, Ms. Wiseman was instrumental in the design and deployment of workflows and systems at major cancer centers around the country.  Ms. Wiseman has held positions as a Registered Nurse in hospital and home health care institutions and as Clinical Implementation Manager at CareTools, Inc., a healthcare information system company.

Ms. Wiseman is a graduate of the Beth Israel Hospital School of Nursing, Boston, MA, and holds a B.S. in Health Care Administration from Emmanuel College.Back to Top ⇧

Board of Directors

  • Connect on LinkedIn

Dr. James A. Manganello

Chairman of the Board
Dr. Manganello joined Provia as the Chairman of the Board and consultant.  Clinically trained in the Department of Psychiatry at Harvard Medical School & the Massachusetts General Hospital, he earned his post-doctorate Masters in Public Health from the Harvard School of Public Health. Over the last 35 years, Dr. Manganello has been an entrepreneur in multiple settings involving outpatient health care delivery, medical device company start-ups and international consulting to health care delivery systems. He most recently co-founded, developed and sold a medical device company yielding significant returns for investors.  He is on the Board of privately held companies as well as not-for-profit organizations.
Dr. Manganello actively consults Officials at the United Nations and World Health Organization on matters of Psychiatry and Public Health.Back to Top ⇧

James Sigler

Member of the Board
Mr. Sigler was formerly a director of ViaCord (now part of PerkinElmer). Mr. Sigler has over 24 years of management experience, including 18 years in the development, manufacturing, and quality management of biological, cell therapy, and small molecule products. As an example, he was divisional head of manufacturing when Genzyme Corporation sought and received regulatory approval for Carticel, an autologous cell therapy product.
Mr. Sigler earned an MBA degree from Harvard Business School and a B.S. degree from Cornell University.Back to Top ⇧


  • Connect on LinkedIn

Dr. Deborah Morosini

Dr. Morosini, an MD Pathologist, who also has a Master’s Degree in Social Work, is a voice for cancer patients and strong supporter of stem cell research.

She was inspired by the philanthropic efforts of her sister Dana Reeve, a non-smoker who died from lung cancer and her brother-in-law Christopher Reeve, the late actor, who had a passion for stem cell research for spinal cord injuries and other illnesses.

She is currently on the board of the National Cancer Institute and Lung Cancer Alliance and has spent the past 10 years as a biotech and pharmaceutical professional, and becoming a noted, inspirational speaker to families dealing with medical hardships.

Morosini joined Store-A-Tooth following her position with AstraZeneca Pharmaceuticals working in the area of research and development of cancer drugs and strategies. Additionally she has contributed to the development of a data element taxonomy (DET) of disease models for use by genomic researchers as part of the federal government’s National Institute of Standards and Technology Program.

Dr. Morosini holds an MD in Anatomic & Clinical Pathology from Boston University School of Medicine.

Dr. Gerry Curatola

Dr. Curatola, dentist, author and humanitarian is best known for his clinical contributions in cosmetic dentistry and wellness.

Dr. Curatola cofounded CS Bioscience Inc., a dental biotech company, and currently serves as its Chairman of the Board. The company performs research and development of pioneering natural therapeutics that promote oral health. In addition, Dr. Curatola is the founder of Rejuvenation Dentistry, a wellness-focused global network of dental practices, and the co-inventor and co-developer of REVITIN Oral Therapy. Dr. Curatola has private dental practices in both Manhattan and East Hampton, New York.

Dr. Jorge L. Castillo

Dr. Castillo is a Diplomate of the American Board of Pediatric Dentistry.

He is the Past-President of the Peruvian Society of Pediatric Dentistry and President of the Peruvian Society of Orthodontics.

He is a member of multiple local and international dental associations. Dr. Castillo is a member of the Editorial Board of several indexed international journals.

He is professor of the Department of Dentistry for Children and Adolescents at the Universidad Peruana Cayetano Heredia and Affiliate Assistant Professor of the Department of Public Health Sciences at the University of Washington.

He has authored several articles published in indexed journals and has lectured in Peru and other countries.

Dr. Martin Ferguson

Dr. Ferguson is a consultant to pharmaceutical and life science informatics companies, and federal agencies engaged in or supporting translational biomedical research.

He focuses on implementing complete ethical, legal, technical, clinical and informatics solutions for human subjects research involving clinically annotated biospecimens.

Prior, he was a founder of Ardais Corporation and co-developed the bioethical and legal frameworks under which the company worked with academic medical centers to bank "human subjects" data and biospecimens that were then distributed to industry and academic researchers.

Dr. Ferguson received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University.

Dr. Paul Krasner

Dr. Paul Krasner, clinical professor of endodontics at Temple University School of Dentistry, received his D.D.S. from Temple University in 1971 and a Certificate in Endodontology from Kingsbrook Jewish Medical Center (New York) in 1975.

He completed general practice residencies at Berkshire Medical Center in 1972 and Queens General Hospital/Long Island Jewish Hospital in 1973.

Dr. Krasner has been a faculty member of the department since 1977 and is a Diplomate of the American Board of Endodontics. He has a private practice in Pottstown, Pennsylvania.

Dr. Joseph Laning, PhD

Dr. Joseph Laning is an experienced executive, manager and scientist with over 16 years' experience in the fields of wound care, regenerative medicine, and cell therapy.

He began his career at Organogenesis, Inc. where he developed and implemented pre-clinical investigations and subsequently managed all patient immunology safety testing leading to the PMA approval of Apligraf™.

In 2002, he joined ViaCell, Inc. where he served as Director of Therapeutic Development and subsequently Senior Director of Analytical Biology. In these roles he oversaw strategic and operational scientific plans leading to successful approval of both IND and IDE FDA filings and completion of the company’s cell therapy clinical trial.

As part of these efforts Dr. Laning managed numerous scientific joint ventures with Amgen, J&J, and Alnylam investigating combinatorial stem cell product development initiatives in cardiac repair and hematopoietic reconstitution. He subsequently brought his extensive experience in scientific management and product development to scientific and business consulting opportunities in industry and academics as Founder and Principal of JCLaning Bio-Consulting.

Most recently he joined the Massachusetts Human Stem Cell Bank and Registry as Executive Director eager to complete the important tasks required to develop the Bank & Registry into the world class resource envisioned at its inception. He received his BA in Biology from Boston University and his PhD in Immunology from Harvard University.

Dr. Nicholas Perrotta, DMD

Dr. Nicholas Perrotta graduated from Tufts University School of Dental Medicine and received his DMD in 1988 and received his residency training at Albert Einstein Medical Center in New York.

Dr. Perrotta was a clinical retorative instructor at Tufts University School of Dental Medicine.

He currently owns a private practice since 1990 in Medord, Ma and sits on many executive dental boards, including his role as President of the East Middlesex District Dental Society.

Dr.Perrotta is a member of American Dental Society, Massachusetts Dental Society, East Middlesex District Dental Society and the American Dental Implant Association and been involved with stem cell technology since 2005.

Dr. Paul T. Sharpe

Paul T. Sharpe is the Dickinson Professor of craniofacial biology and the Director of Research at the Dental Institute, King's College London, London, UK.

He graduated with a degree in biology from York University (1977) and a Ph.D. degree in biochemistry from Sheffield University, UK (1981).

He has published in excess of 200 research papers and supervised over 30 Ph.D. students.

Dr. Sharpe is the founder of Odontis, a company developing a biological replacement tooth product.

In 2006, Dr. Sharpe's paper "Stem cell-based tissue engineering of teeth" received the William J. Gies Award for best publication in biomaterials and bioengineering from the same organization.

Dr. Jim Vaught, Ph.D.

Dr. Jim Vaught spent 14 years (1999-2013) at the U.S. National Cancer Institute (NCI), most recently as the Chief of the Biorepositories and Biospecimen Research Branch (BBRB) in the Cancer Diagnosis Program.

He has been working in the field of biorepository and biospecimen science for over 20 years. In 1999, he was one of the founding members of the International Society for Biological & Environmental Repositories (ISBER) and was its second President.

He serves as vice chair of the ISBER Publications Committee and co-chair of the International Resource Locator Working Group.

He serves on a number of biobank advisory groups including the Telethon-Italy Genetic Biobank Network; the Stellenbosch University (Cape Town) H3-Africa Governance Advisory Panel; and the Biobanques Network (France) Scientific Board.

In addition to ISBER, Dr. Vaught is a member of the American Association for Cancer Research (AACR), the American Society for Pharmacology and Experimental Therapeutics, the European Society for Biopreservation & Biobanking and the American Association for Clinical Chemistry.

He is the author of nearly 70 peer-reviewed articles and book chapters.

From 2006 to 2012 he was Senior Editor for Biospecimens and Biorepositories for the AACR journal Cancer Epidemiology, Biomarkers and Prevention.

In 2012 he became Editor-in-Chief of Biopreservation and Biobanking, the official journal of ISBER. He is currently a Senior Research Fellow at the International Prevention Research Institute (Lyon).

Dr. Vaught is the President-Elect of ISBER for 2014-2015.

About Provia

Provia Laboratories, LLC is a healthcare services company specializing in high quality biobanking. The company advises industrial, academic, and governmental clients on matters related to the preservation of biological specimens for research and clinical use.

Contact Us

Ph. (781) 862-0700
Fax: (877) 867 8753